Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).
Fidock MD, Souberbielle BE, Laxton C, Rawal J, Delpuech-Adams O, Corey TP, Colman P, Kumar V, Cheng JB, Wright K, Srinivasan S, Rana K, Craig C, Horscroft N, Perros M, Westby M, Webster R, van der Ryst E. Fidock MD, et al. Among authors: westby m. Clin Pharmacol Ther. 2011 Jun;89(6):821-9. doi: 10.1038/clpt.2011.60. Epub 2011 Mar 30. Clin Pharmacol Ther. 2011. PMID: 21451504 Clinical Trial.
Preclinical studies of PF-04849285, an interferon-α8 fusion protein for the treatment of HCV.
Flores MV, Hickling TP, Sreckovic S, Fidock MD, Horscroft N, Katragadda M, Savic B, Rawal J, Delpuech-Adams OE, Robas N, Corey T, Nelms L, Lawton M, Marcek J, Stubbs M, Westby M, Ciaramella G. Flores MV, et al. Among authors: westby m. Antivir Ther. 2012;17(5):869-81. doi: 10.3851/IMP2099. Epub 2012 Apr 13. Antivir Ther. 2012. PMID: 22505586
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).
Stupple PA, Batchelor DV, Corless M, Dorr PK, Ellis D, Fenwick DR, Galan SR, Jones RM, Mason HJ, Middleton DS, Perros M, Perruccio F, Platts MY, Pryde DC, Rodrigues D, Smith NN, Stephenson PT, Webster R, Westby M, Wood A. Stupple PA, et al. Among authors: westby m. J Med Chem. 2011 Jan 13;54(1):67-77. doi: 10.1021/jm100978n. Epub 2010 Dec 3. J Med Chem. 2011. PMID: 21128663
CCR5 pharmacology methodologies and associated applications.
Mansfield R, Able S, Griffin P, Irvine B, James I, Macartney M, Miller K, Mills J, Napier C, Navratilova I, Perros M, Rickett G, Root H, van der Ryst E, Westby M, Dorr P. Mansfield R, et al. Among authors: westby m. Methods Enzymol. 2009;460:17-55. doi: 10.1016/S0076-6879(09)05202-1. Methods Enzymol. 2009. PMID: 19446719
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M. Dorr P, et al. Among authors: westby m. Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32. doi: 10.1128/AAC.49.11.4721-4732.2005. Antimicrob Agents Chemother. 2005. PMID: 16251317 Free PMC article.
130 results